吉西他滨单药及联合奈达铂治疗老年晚期非小细胞肺癌62例的临床分析

目的观察吉西他滨单药及联合奈达铂对老年晚期非小细胞肺癌的疗效及不良反应。方法62例晚期老年非小细胞肺癌患者随机分为两组，吉西他滨联合奈达铂组31例，吉西他滨单药组31例。两组患者一般资料有可比性（P〉0．05）。结果联合组和单药组的有效率分别为35．5％、29．O％；中位生存期分别为10．6个月、9．7个月，疾病缓解时间分别为5．5个月、5．2个月；以上观察指标两组均无统计学意义（P〉0．05）。两组骨髓抑制及肝肾功能损害发生率无统计学意义（P〉0．05），但恶心、呕吐等胃肠道反应单药组较联合组明显降低（P〈0．05），且单药组KPS改善率高于联合组（P〉0．05）。结论吉西他滨单药与吉西他滨联合奈达铂治疗老年晚期非小细胞肺癌疗效相似，但不良反应轻。有助于提高生活质量，吉西他滨单药化疗更适合老年晚期非小细胞肺癌的治疗。

Clinical study of gemcitabine single-agent and gemcitabine plus nedaplatin in the treatment of elder patients with advanced non-small cell lung cancer

Objective To evaluate the clinical efficacy and adverse reactions of gemcitabine single-agent and gemcitabine plus Nedaplatin regimen for elder patients with advanced non-small cell lung cancer.Methods All of 62 cases of elder patients with advanced non-small cell lung cancer were randomly divided into the gemcitabine plus Nedaplatin regimen group(GP,31 cases) and the gemcitabine regimen group(G,31 cases).Patients in both groups were well-matched with baseline disease characteristics(P > 0.05).Results The response rates of GP and G group were 35.5% and 29.0% respectively.The median survival time(MST) of GP and G group were 10.6 months and 9.7 months respectively,and the disease remission time(DRT) were 5.5 months and 5.2 months respectively.There was no significant difference(P > 0.05) between two groups.The occurrence rates of myelosuppression,hepatic defect and renal defect had no significant difference between two groups(P > 0.05),but the occurrence rate of nausea ﹠vomiting in the G group was lower than it in the GP group(P < 0.05),and with regard to the improvement of the quality of life,the G group was higher than GP group.Conclusion The curative effects by G and GP treatment for advanced NSCLC of the old age are similar,but the toxicity responses are more endurable with better quality of life in G group.So from the adverse reactions and tolerability,single-agent gemcitabine(G) treatment is more suitable for elderly patients with advanced non-small cell lung cancer.